Due to its course, multiple myeloma may negatively affect the functioning of patients. Different treatment methods are also associated with patients' varying perception of their health condition. The purpose of this study is to determine the disease-specific complaints among multiple myeloma patients during selected treatment methods-chemotherapy, autologous hematopoietic stem cell transplantation, and supportive therapy. The study group included 246 patients (98 in the chemotherapy group, of which 87 in the autologous hematopoietic stem cell transplantation group and 61 in the supportive therapy group). The study was conducted between August 2020 and December 2021 with the EORTC QLQ-MY20 questionnaire. According to the study results, patients treated with chemotherapy had the highest degree of disease symptom severity and side effects of treatment as well as the lowest assessment of their perspectives for the future. Patients who received supportive treatment had the lowest degree of disease symptom severity and side effects of treatment, and also assessed their body image and future perspectives the highest. Women assessed their future perspectives significantly lower than men. The severity of disease symptoms experienced by patients increases with age.

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-024-82301-1DOI Listing

Publication Analysis

Top Keywords

multiple myeloma
12
supportive therapy
12
disease-specific complaints
8
complaints multiple
8
myeloma patients
8
patients treated
8
treated chemotherapy
8
autologous hematopoietic
8
hematopoietic stem
8
stem cell
8

Similar Publications

Antisense oligonucleotides-based approaches for the treatment of multiple myeloma.

Int J Biol Macromol

December 2024

Faculty of Medical Engineering, National University of Science and Technology Politehnica Bucharest, Gheorghe Polizu 1-7, 011061 Bucharest, Romania; Advanced Polymer Materials Group, University Politehnica of Bucharest, Gheorghe Polizu 1-7, 011061 Bucharest, Romania; ebio-Hub Research Centre, University Politehnica of Bucharest-Campus, Iuliu Maniu 6, 061344 Bucharest, Romania. Electronic address:

Multiple myeloma (MM), a hematological malignancy which affects the monoclonal plasma cells in the bone marrow, is in rising incidence around the world, accounting for approximately 2 % of newly diagnosed cancer cases in the US, Australia, and Western Europe. Despite the progress made in the last few years in the available therapeutic options (e.g.

View Article and Find Full Text PDF

Genetic architecture of Multiple Myeloma and its prognostic implications - An updated review.

Malays J Pathol

December 2024

Universiti Sains Malaysia, School of Medical Sciences, Human Genome Centre, Health Campus, Kelantan, Malaysia.

Multiple myeloma (MM), a clonal B-cell neoplasia, is an incurable and heterogeneous disease where survival ranges from a few months to more than 10 years. The clinical heterogeneity of MM arises from multiple genomic events that result in tumour development and progression. Recurring genomic abnormalities including cytogenetic abnormalities, gene mutations and abnormal gene expression profiles in myeloma cells have a strong prognostic power.

View Article and Find Full Text PDF

Due to its course, multiple myeloma may negatively affect the functioning of patients. Different treatment methods are also associated with patients' varying perception of their health condition. The purpose of this study is to determine the disease-specific complaints among multiple myeloma patients during selected treatment methods-chemotherapy, autologous hematopoietic stem cell transplantation, and supportive therapy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!